Abstract
Objective
This study aimed to describe, optimize and evaluate a method for preparing multivalent conjugate vaccines by simultaneous conjugation of two different bacterial capsular polysaccharides (CPs) with tetanus toxoid (TT) as bivalent conjugates.
Methods
Different molecular weights (MWs) of polysaccharides, activating agents and capsular polysaccharide/protein (CP/Pro) ratio that may influence conjugation and immunogenicity were investigated and optimized to prepare the bivalent conjugate bulk. Using the described method and optimized parameters, a 20-valent pneumococcal conjugate vaccine and a bivalent meningococcal vaccine were developed and their effectiveness was compared to that of corresponding licensed vaccines in rabbit or mouse models.
Results
The immunogenicity test revealed that polysaccharides with lower MWs were better for Pn1-TT-Pn3 and MenA-TT-MenC, while higher MWs were superior for Pn4-TT-Pn14, Pn6A-TT-Pn6B, Pn7F-TT-Pn23F and Pn8-TT-Pn11A. For activating polysaccharides, 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) was superior to cyanogen bromide (CNBr), but for Pn1, Pn3 and MenC, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDAC) was the most suitable option. For Pn6A-TT-Pn6B and Pn8-TT-Pn11A, rabbits immunized with bivalent conjugates with lower CP/Pro ratios showed significantly stronger CP-specific antibody responses, while for Pn4-TT-Pn14, higher CP/Pro ratio was better. Instead of interfering with the respective immunological activity, our bivalent conjugates usually induced higher IgG titers than their monovalent counterparts.
Conclusion
The result indicated that the described conjugation technique was feasible and efficacious to prepare glycoconjugate vaccines, laying a solid foundation for developing extended-valent multivalent or combined conjugate vaccines without potentially decreased immune function.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Pace D. Glycoconjugate vaccines. Expert Opin Biol Ther, 2013,13(1):11–33
Principi N, Esposito S. Development of pneumococcal vaccines over the last 10 years. Expert Opin Biol Ther, 2018,18(1):7–17
Masomian M, Ahmad Z, Gew LT, et al. Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines. 2020,8(1):132
Oligbu G. Higher Valent Pneumococcal Conjugate Vaccines: is it a roller coaster? AIMS Public Health, 2020,7(1):29–32
Pelton SI. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines. J Adolesc Health, 2016,59(2, Supplement):S3–S11
Adamo R, Nilo A, Harfouche C, et al. Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease. Glycoconjugate J, 2014,31(9):637–647
Méndez Y, Chang J, Humpierre AR, et al. Multicomponent polysaccharide—protein bioconjugation in the development of antibacterial glycoconjugate vaccine candidates. Chem Sci, 2018,9(9):2581–2588
Humpierre AR, Zanuy A, Saenz M, et al. Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates. Bioconjugate Chem, 2020,31(9): 2231–2240
Lees A, Nelson BL, Mond JJ. Activation of soluble polysaccharides with 1-cyano-4-dimethy-laminopyridinium tetrafluoroborate for use in protein—polysaccharide conjugate vaccines and immunological reagents. Vaccine, 1996,14(3):190–198
Chu C, Schneerson R, Robbins JB, et al. Further Studies on the Immunogenicity of Haemophilus influenzae Type b and Pneumococcal Type 6A Polysaccharide-Protein Conjugates. Infect Immun, 1983,40(1):245–256
Berti F, Romano MR, Micoli F, et al. Relative stability of meningococcal serogroup A and X polysaccharides. Vaccine, 2012,30(45):6409–6415
Thompson A, Lamberth E, Severs J, et al. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine, 2019,37(42):6201–6207
Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine, 2007,25(33):6164–6166
Berti F, Micoli F. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs. Curr Opin Immunol, 2020,65:42–49
Bröker M, Berti F, Costantino P. Factors contributing to the immunogenicity of meningococcal conjugate vaccines. Hum Vacc Immunother, 2016, 12(7):1808–1824
Biemans R, Micoli F, Romano MR. 8-Glycoconjugate vaccines, production and characterization. In: Rauter AP, BE Christensen, L Somsák, et al., eds. Recent Trends in Carbohydrate Chemistry: Elsevier, 2020:285–313
Avci F, Berti F, Dull P, et al. Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development. mSphere, 2019,4(5):e00520–00519
Micoli F, Del Bino L, Alfini R, et al. Glycoconjugate vaccines: current approaches towards faster vaccine design. Expert Rev Vaccines, 2019,18(9):881–895
Rana R, Dalal J, Singh D, et al. Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysacc-haride chain lengths. Vaccine, 2015,33(23):2646–2654
Lockyer K, Gao F, Francis RJ, et al. Higher mass meningococcal group C-tetanus toxoid vaccines conjugated with carbodiimide correlate with greater immunogenicity. Vaccine, 2020,38(13):2859–2869
Laferriere CA, Sood RK, De Muys JM, et al. Streptococcus pneumoniae Type 14 Polysaccharide-Conjugate Vaccines: Length Stabilization of Opsono-phagocytic Conformational Polysaccharide Epitopes. Infect Immun, 1998,66(6):2441–2446
Laferrière CA, Sood RK, De Muys J-M, et al. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine, 1997,15(2):179–186
Kaplonek P, Khan N, Reppe K, et al. Improving vaccines against Streptococcus pneumoniae using synthetic glycans. Proc Natl Acad Sci, 2018, 115(52):13353–13358
Schumann B, Reppe K, Kaplonek P, et al. Development of an Efficacious, Semisynthetic Glycoconjugate Vaccine Candidate against Streptococcus pneumoniae Serotype 1. ACS Cent Sci, 2018,4(3):357–361
Javed, Mandal PK. Bacterial surface capsular polysaccharides from Streptococcus pneumoniae: A systematic review on structures, syntheses, and glycoconjugate vaccines. Carbohydr Res, 2021,502: 108277
Schneerson R, Barrera O, Sutton A, et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med, 1980,152(2):361–376
Frasch CE. Preparation of bacterial polysaccharide—protein conjugates: Analytical and manufacturing challenges. Vaccine, 2009,27(46):6468–6470
Jin Z, Chu C, Robbins JB, et al. Preparation and Characterization of Group A Meningococcal Capsular Polysaccharide Conjugates and Evaluation of Their Immunogenicity in Mice. Infect Immun, 2003,71(9):5115–5120
Avci FY, Li X, Tsuji M, et al. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med, 2011,17(12):1602–1609
Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A review. Vaccine, 2010,28(34):5513–5523
Woodruff MC, Kim EH, Luo W, et al. B Cell Competition for Restricted T Cell Help Suppresses Rare-Epitope Responses. Cell Rep, 2018,25(2):321–327.e323
Fattom A, Cho YH, Chu C, et al. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine, 1999,17(2):126–133
Porro M, Costantino P, Giovannoni F, et al. A molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for gram-positive and gram-negative encapsulated bacteria. Mol Immunol, 1986,23(4):385–391
Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers. Pediatrics, 2010,126 (3):e493–e505
Fitz-Patrick D, Young Jr M, Scott DA, et al. Arandomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States. Hum Vacc Immunother, 2021,17(7):1–8
Caro-Aguilar I, Indrawati L, Kaufhold RM, et al. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain. Vaccine, 2017,35(6):865–872
Acknowledgments
We would like to thank Ping XUE for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors have no conflict of interest.
Rights and permissions
About this article
Cite this article
Huang, F., Jing, Xb., Li, Yb. et al. Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models. CURR MED SCI 43, 22–34 (2023). https://doi.org/10.1007/s11596-022-2652-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-022-2652-y